Taken together, despite the discrepancy in the literature, we have placed a diagnostic and therapeutic value on miR-146a-5p and its direct target TRAF6 as part of the molecular signature marking NSCLC development. This evidence concerns the gene TRAF6 and non-small cell lung carcinoma.